The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects
Open accessAbstract
Multiple lentigines/LEOPARD syndrome (LS) is a rare, autosomal dominant disorder characterized by Lentigines, Electrocardiogram abnormalities, Ocular hypertelorism, Pulmonic valvular stenosis, Abnormalities of genitalia, Retardation of growth, and Deafness. Like the more common Noonan syndrome (NS), LS is caused by germ line missense mutations in PTPN11, encoding the protein-tyrosine phosphatase Shp2. Enzymologic, structural, cell biological, and mouse genetic studies indicate that NS is caused by gain-of-function PTPN11 mutations. Because NS and LS share several features, LS has been viewed as an NS variant. We examined a panel of LS mutants, including the two most common alleles. Surprisingly, we found that in marked contrast to NS, LS mutants are catalytically defective and act as dominant negative mutations that interfere with growth factor/Erk-mitogen-activated protein kinase-mediated signaling. Molecular modeling and biochemical studies suggest that LS mutations contort the Shp2 catalytic domain and result in open, inactive forms of Shp2. Our results establish that the pathogenesis of LS and NS is distinct and suggest that these disorders should be distinguished by mutational analysis rather than clinical presentation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Migration: Integrating Signals from Front to Back
Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., Parsons, J. T., & Horwitz, A. R. (2003) · Science · doi:10.1126/science.1092053 · Cited by 4,978
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., et al. (2001) · Nature Genetics · doi:10.1038/ng772 · Cited by 1,733
The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
Neel, B. G., Gu, H., & Pao, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00091-4 · Cited by 1,249
Self-citationTartaglia, M., Niemeyer, C. M., Fragale, A., Song, X., Buechner, J., Jung, A., Hählen, K., Hasle, H., Licht, J. D., & Gelb, B. D. (2003) · Nature Genetics · doi:10.1038/ng1156 · Cited by 1,033
Crystal Structure of the Tyrosine Phosphatase SHP-2
Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M. J., & Shoelson, S. E. (1998) · Cell · doi:10.1016/s0092-8674(00)80938-1 · Cited by 985
Crystal Structure of Human Protein Tyrosine Phosphatase 1B
Barford, D., Flint, A. J., & Tonks, N. K. (1994) · Science · doi:10.1126/science.8128219 · Cited by 758
Self-citationHeart Valve Development: Endothelial Cell Signaling and Differentiation
Armstrong, E. J., & Bischoff, J. (2004) · Circulation Research · doi:10.1161/01.res.0000141146.95728.da · Cited by 647
Structural Basis for Phosphotyrosine Peptide Recognition by Protein Tyrosine Phosphatase 1B
Jia, Z., Barford, D., Flint, A. J., & Tonks, N. K. (1995) · Science · doi:10.1126/science.7540771 · Cited by 581
Self-citationBentires-Alj, M., Paez, J. G., David, F. S., Keilhack, H., Halmos, B., Naoki, K., Maris, J. M., Richardson, A., Bardelli, A., Sugarbaker, D. J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1923 · Cited by 509
Self-citationAbnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2
Saxton, T. M., Henkemeyer, M., Gasca, S., Shen, R., Rossi, D. J., Shalaby, F., Feng, G.-S., & Pawson, T. (1997) · The EMBO Journal · doi:10.1093/emboj/16.9.2352 · Cited by 480
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
Loh, M. L. (2004) · Blood · doi:10.1182/blood-2003-09-3287 · Cited by 427
Grouping of Multiple-Lentigines/LEOPARD and Noonan Syndromes on the PTPN11 Gene
Digilio, M. C., Conti, E., Sarkozy, A., Mingarelli, R., Dottorini, T., Marino, B., Pizzuti, A., & Dallapiccola, B. (2002) · The American Journal of Human Genetics · doi:10.1086/341528 · Cited by 421
Araki, T., Mohi, M. G., Ismat, F. A., Bronson, R. T., Williams, I. R., Kutok, J. L., Yang, W., Pao, L. I., Gilliland, D. G., Epstein, J. A., et al. (2004) · Nature Medicine · doi:10.1038/nm1084 · Cited by 420
Self-citationDefective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling
Jackson, L. F. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg264 · Cited by 417
NOONAN SYNDROME AND RELATED DISORDERS: Genetics and Pathogenesis
Tartaglia, M., & Gelb, B. D. (2005) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.6.080604.162305 · Cited by 355
Form and Function in Protein Dephosphorylation
Denu, J. M., Stuckey, J. A., Saper, M. A., & Dixon, J. E. (1996) · Cell · doi:10.1016/s0092-8674(00)81356-2 · Cited by 330
Camenisch, T. D., Schroeder, J. A., Bradley, J., Klewer, S. E., & McDonald, J. A. (2002) · Nature Medicine · doi:10.1038/nm742 · Cited by 329
Gorlin, R. J. (1969) · American Journal of Diseases of Children · doi:10.1001/archpedi.1969.02100030654006 · Cited by 323
Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2
Barford, D., & Neel, B. G. (1998) · Structure · doi:10.1016/s0969-2126(98)00027-6 · Cited by 321
Self-citationMice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis
Chen, B., Bronson, R. T., Klaman, L. D., Hampton, T. G., Wang, J.-F., Green, P. J., Magnuson, T., Douglas, P. S., Morgan, J. P., & Neel, B. G. (2000) · Nature Genetics · doi:10.1038/73528 · Cited by 301
Self-citationDiverse Biochemical Properties of Shp2 Mutants
Keilhack, H., David, F. S., McGregor, M., Cantley, L. C., & Neel, B. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504699200 · Cited by 298
Self-citationZhang, S. Q., Tsiaras, W. G., Araki, T., Wen, G., Minichiello, L., Klein, R., & Neel, B. G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.12.4062-4072.2002 · Cited by 282
Self-citationMohi, M. G., Williams, I. R., Dearolf, C. R., Chan, G., Kutok, J. L., Cohen, S., Morgan, K., Boulton, C., Shigematsu, H., Keilhack, H., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.010 · Cited by 277
Self-citationPTPN11 mutations in LEOPARD syndrome
Legius, E., Schrander-Stumpel, C., Schollen, E., Pulles-Heintzberger, C., Gewillig, M., & Fryns, J.-P. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.8.571 · Cited by 274
Multiple Requirements for SHPTP2 in Epidermal Growth Factor-Mediated Cell Cycle Progression
Bennett, A. M., Hausdorff, S. F., O’Reilly, A. M., Freeman, R. M., & Neel, B. G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.1189 · Cited by 246
Self-citationNoonan syndrome: The changing phenotype
Allanson, J. E., Hall, J. G., Hughes, H. E., Preus, M., Witt, R. D., Opitz, J. M., & Reynolds, J. F. (1985) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320210313 · Cited by 239
Pannifer, A. D. B., Flint, A. J., Tonks, N. K., & Barford, D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.17.10454 · Cited by 237
Self-citationShi, Z.-Q., Yu, D.-H., Park, M., Marshall, M., & Feng, G.-S. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.5.1526-1536.2000 · Cited by 228
Fragale, A., Tartaglia, M., Wu, J., & Gelb, B. D. (2004) · Human Mutation · doi:10.1002/humu.20005 · Cited by 194
Lakkis, M. M., & Epstein, J. A. (1998) · Development · doi:10.1242/dev.125.22.4359 · Cited by 183
Nf1 has an essential role in endothelial cells
Gitler, A. D., Zhu, Y., Ismat, F. A., Lu, M. M., Yamauchi, Y., Parada, L. F., & Epstein, J. A. (2003) · Nature Genetics · doi:10.1038/ng1059 · Cited by 168
High incidence of malformation syndromes in a series of 1,073 children with cancer
Merks, J. H. M., Caron, H. N., & Hennekam, R. C. M. (2005) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30603 · Cited by 163
Clinical and molecular analysis of 30 patients with multiple lentigines LEOPARD syndrome
Sarkozy, A., Conti, E., Digilio, M. C., Marino, B., Morini, E., Pacileo, G., Wilson, M., Calabrò, R., Pizzuti, A., & Dallapiccola, B. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.013466 · Cited by 159
Chan, R. J., Leedy, M. B., Munugalavadla, V., Voorhorst, C. S., Li, Y., Yu, M., & Kapur, R. (2005) · Blood · doi:10.1182/blood-2004-10-4002 · Cited by 156
Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia
Niihori, T., Aoki, Y., Ohashi, H., Kurosawa, K., Kondoh, T., Ishikiriyama, S., Kawame, H., Kamasaki, H., Yamanaka, T., Takada, F., et al. (2005) · Journal of Human Genetics · doi:10.1007/s10038-005-0239-7 · Cited by 147
The protein tyrosine phosphatase Shp-2 regulates RhoA activity
Schoenwaelder, S. M., Petch, L., Williamson, D., Shen, R., Feng, G., & Burridge, K. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00831-9 · Cited by 134
Activated Mutants of SHP-2 Preferentially Induce Elongation of Xenopus Animal Caps
O’Reilly, A. M., Pluskey, S., Shoelson, S. E., & Neel, B. G. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.1.299-311.2000 · Cited by 125
Self-citationSHP-2 Positively Regulates Myogenesis by Coupling to the Rho GTPase Signaling Pathway
Kontaridis, M. I., Eminaga, S., Fornaro, M., Zito, C. I., Sordella, R., Settleman, J. E., & Bennett, A. M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.12.5340-5352.2004 · Cited by 116
Self-citationTyrosine phosphatase activity in mitochondria: presence of Shp-2 phosphatase in mitochondria
Salvi, M., Stringaro, A., Brunati, A. M., Agostinelli, E., Arancia, G., Clari, G., & Toninello, A. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4211-z · Cited by 89
PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience
Keren, B., Hadchouel, A., Saba, S., Sznajer, Y., Bonneau, D., Leheup, B., Boute, O., Gaillard, D. A., Lacombe, D., Layet, V., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.021451 · Cited by 88
Krenz, M., Yutzey, K. E., & Robbins, J. M. (2005) · Circulation Research · doi:10.1161/01.res.0000186194.06514.b0 · Cited by 66
Mechanism-based combination telomerase inhibition therapy
Shay, J. W., & Wright, W. E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.12.012 · Cited by 61
Cited by
Protein tyrosine phosphatases: from genes, to function, to disease
Tonks, N. K. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2039 · Cited by 1,677
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Ras in Cancer and Developmental Diseases
Fernandez-Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 897
Rauen, K. A. (2013) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091212-153523 · Cited by 879
The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation
Tidyman, W. E., & Rauen, K. A. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.04.001 · Cited by 780
Metadata
- Authors
- Kontaridis, M. I., Swanson, K. D., David, F. S., Barford, D., & Neel, B. G.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-03
- Volume
- 281
- Issue
- 10
- Pages
- 6785-6792
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2124171936
- Cited by
- 338
- References
- 43
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.